Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.

Clin Cancer Res · 2022 · PMC9475241 · PMID 35674661

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For the comparison with BR, ORR and CR rate for tafasitamab plus lenalidomide were more than 10% higher but did not reach statistical significance with the given sample size of 75 patient pairs ( Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.